Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shelley McCormick

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
JAMA Dermatology|May 27, 2026
Human Genome Promise-Are We There Yet?Soo Hyun Kim, Shelley McCormick, Hensin Tsao
Journal of Genetic Counseling|March 5, 2022
Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on ATM and CHEK2Shelley McCormick, Stephanie Hicks, Mackenzie Wooters, et al.
Journal of Genetic Counseling|March 20, 2025
Experiences and expectations of hereditary colorectal cancer patients during the post-genetic test periodEmily Stuebing, Jessica Jonas, Shelley McCormick, et al.
Journal of Genetic Counseling|August 9, 2022
Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical centerCaitlin M Finn, Shelley McCormick, Danielle Peterson, et al.
Scientific Reports|October 14, 2020
Cancer risks associated with the germline MITF(E318K) variantSamantha M Guhan, Mykyta Artomov, Shelley McCormick, et al.
The Journal of Clinical Investigation|January 2, 2026
Germline inactivation of tumor suppressor BAP1 is associated with white spottingChing-Ni Njauw, Zhenyu Ji, David I Latoni, et al.
Journal of Telemedicine and Telecare|November 15, 2021
Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomesSavannah Binion, Lia J Sorgen, Beth N Peshkin, et al.
JNCI Cancer Spectrum|July 16, 2019
Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-UpMary K Interrante, Hannah Segal, Beth N Peshkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancerMarc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, et al.
Journal of the American Academy of Dermatology|March 21, 2024
Germline cancer susceptibility in individuals with melanomaPauline Funchain, Ying Ni, Brandie Heald, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
JAMA Dermatology|May 27, 2026
Human Genome Promise-Are We There Yet?Soo Hyun Kim, Shelley McCormick, Hensin Tsao
Journal of Genetic Counseling|March 5, 2022
Toward a better understanding of the experience of patients with moderate penetrance breast cancer gene pathogenic/likely pathogenic variants: A focus on ATM and CHEK2Shelley McCormick, Stephanie Hicks, Mackenzie Wooters, et al.
Journal of Genetic Counseling|March 20, 2025
Experiences and expectations of hereditary colorectal cancer patients during the post-genetic test periodEmily Stuebing, Jessica Jonas, Shelley McCormick, et al.
Journal of Genetic Counseling|August 9, 2022
Motivation and family communication in hereditary prostate cancer genetic testing: Survey of patients from a US tertiary medical centerCaitlin M Finn, Shelley McCormick, Danielle Peterson, et al.
Scientific Reports|October 14, 2020
Cancer risks associated with the germline MITF(E318K) variantSamantha M Guhan, Mykyta Artomov, Shelley McCormick, et al.
The Journal of Clinical Investigation|January 2, 2026
Germline inactivation of tumor suppressor BAP1 is associated with white spottingChing-Ni Njauw, Zhenyu Ji, David I Latoni, et al.
Journal of Telemedicine and Telecare|November 15, 2021
Telephone versus in-person genetic counseling for hereditary cancer risk: Patient predictors of differential outcomesSavannah Binion, Lia J Sorgen, Beth N Peshkin, et al.
JNCI Cancer Spectrum|July 16, 2019
Randomized Noninferiority Trial of Telephone vs In-Person Genetic Counseling for Hereditary Breast and Ovarian Cancer: A 12-Month Follow-UpMary K Interrante, Hannah Segal, Beth N Peshkin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2014
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancerMarc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, et al.
Journal of the American Academy of Dermatology|March 21, 2024
Germline cancer susceptibility in individuals with melanomaPauline Funchain, Ying Ni, Brandie Heald, et al.
Pageof 1